FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers Jun 29, 2018 7:00am EDT
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association Jun 15, 2018 8:00am EDT
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China Jun 14, 2018 7:05am EDT
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 Jun 04, 2018 7:04am EDT
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC May 31, 2018 7:04am EDT
Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association May 17, 2018 11:43am EDT
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018 May 01, 2018 7:30am EDT
